Business
InMode Expects Record Fourth Quarter and Full Year 2020 Results, Fourth Quarter Revenue Between $74.5-$75M, Non-GAAP Earnings per Diluted Share Between $0.91-$0.93; Announces 2021 Full Year Revenue Guidance of $250- $260M
Conference call to be held on February 10 at 8:30 a.m. Eastern Time YOKNEAM, Israel,, Jan. 12, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading
About this update from Inmode Ltd.
[{"type":"text","content":"Conference call to be held on February 10 at 8:30 a.m. Eastern Time\n\n\nYOKNEAM, Israel,, Jan. 12, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2020 before the Nasdaq market opens on Wednesday, February 10, 2021. \n\n \n \n \n \n \n \n\n \nInMode is currently finalizing its financial results for the three months and year ended December 31, 2020. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized. Based on preliminary results, management expects:\nRecord revenue for the fourth quarter and full year of 2020 in the range of $74.5 million to $75 million and $205.5 million to $206 million, respectively, higher than the previously announced guidance of $192 million to $195 million Non-GAAP earnings per diluted share for the fourth quarter and full year of 2020 in the range of $0.91 to $0.93 and $2.08 to $2.10, respectively Non-GAAP gross margin for the full year of 2020 in the range of 84% to 86% Full year 2021 revenue guidance in the range of $250 million to $260 million. \"Our best-in-class sales and marketing team adapted to the new COVID environment seamlessly. We were able to execute on all of our strategic goals throughout the ongoing pandemic. Our unique hands-free and minimally invasive technology supported InMode's growth by providing safe and effective solutions for physicians to offer their patients,\" commented Moshe Mizrahy, InMode's CEO. \n\"Our new proprietary and patented technologies have been well-accepted by the medical community even during this difficult period. These technologies enabled physicians to provide solutions that maintain social distancing for out-patient clinic-based treatments. We believe these treatments are becoming the standard of care in the COVID-19 environment,\" commented Dr. Michael Kreindel, InMode's CTO.\n[1] Please refer to \"Use of Non-GAAP Financial Measure\" below for important information about non-GAAP financial measures. Non-GAAP financial results exclude stock-based com...